| dbo:abstract |
برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن. (ar) Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala. (cs) Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. (en) Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère. (fr) Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года). (ru) |
| dbo:alternativeName |
Siliq, Kyntheum, Lumicef (en) |
| dbo:casNumber |
1174395-19-7 |
| dbo:drugbank |
DB11776 |
| dbo:fdaUniiCode |
6ZA31Y954Z |
| dbo:kegg |
D10061 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/brodalumab |
| dbo:wikiPageID |
33023911 (xsd:integer) |
| dbo:wikiPageLength |
8806 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1124010770 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Amgen dbr:Ustekinumab dbr:Interleukin-17_receptor dbr:Interleukin_17 dbr:LEO_Pharma dbr:Monoclonal_antibody dbr:Amgen dbr:FDA dbr:Ixekizumab dbr:AstraZeneca dbr:Biologics_license_application dbr:Plaque_psoriasis dbr:Kyowa_Hakko_Kirin dbr:Valeant_Pharmaceuticals dbr:Interleukin_17_receptor_A dbr:Primary_endpoint |
| dbp:atcPrefix |
L04 (en) |
| dbp:atcSuffix |
AC12 (en) |
| dbp:c |
6372 (xsd:integer) |
| dbp:casNumber |
1174395 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:dailymedid |
Brodalumab (en) |
| dbp:drugbank |
DB11776 (en) |
| dbp:h |
9840 (xsd:integer) |
| dbp:kegg |
D10061 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceUs |
Brodalumab (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1712 (xsd:integer) |
| dbp:o |
1988 (xsd:integer) |
| dbp:s |
52 (xsd:integer) |
| dbp:source |
u (en) |
| dbp:synonyms |
KHK4827, AMG 827 (en) |
| dbp:target |
dbr:Interleukin_17_receptor_A |
| dbp:tradename |
Siliq, Kyntheum, Lumicef (en) |
| dbp:type |
mab (en) |
| dbp:unii |
6 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
459982905 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Redirect dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Interleukin_receptor_modulators dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub |
| dcterms:subject |
dbc:Amgen |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment |
برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن. (ar) Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala. (cs) Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. (en) Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère. (fr) Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года). (ru) |
| rdfs:label |
Brodalumab (en) برودالوماب (ar) Brodalumab (cs) Brodalumab (fr) Бродалумаб (ru) |
| owl:sameAs |
freebase:Brodalumab yago-res:Brodalumab wikidata:Brodalumab dbpedia-ar:Brodalumab dbpedia-cs:Brodalumab dbpedia-fr:Brodalumab http://or.dbpedia.org/resource/ବ୍ରୋଡାଲୁମାବ dbpedia-ru:Brodalumab https://global.dbpedia.org/id/4caiE |
| prov:wasDerivedFrom |
wikipedia-en:Brodalumab?oldid=1124010770&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Brodalumab |
| is dbo:wikiPageRedirects of |
dbr:Kyntheum dbr:Siliq dbr:C6372H9840N1712O1988S52 |
| is dbo:wikiPageWikiLink of |
dbr:Psoriasis dbr:Bausch_Health dbr:Institute_for_Clinical_and_Economic_Review dbr:Interleukin-17_receptor dbr:Kyntheum dbr:Siliq dbr:Monoclonal_antibody_therapy dbr:C6372H9840N1712O1988S52 dbr:Amgen dbr:Ixekizumab dbr:AstraZeneca dbr:ATC_code_L04 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Br |
| is foaf:primaryTopic of |
wikipedia-en:Brodalumab |